Ben Gewurz graduated from Stanford University. He then received MD-PhD training at Harvard and MIT. He did his post-doctoral studies with Elliott Kieff focused on Epstein-Barr virus oncoprotein LMP1-mediated canonical NF-κB pathway activation. He began his independent laboratory at the Brigham & Women’s in 2012. His laboratory studies Epstein-Barr virus and SARS-CoV-2 pathogenesis and B-cell immunobiology. The Gewurz laboratory uses CRISPR/Cas9, proteomic, genomic and metabolomic approaches to investigate the EBV/host relationship and subversion of key cellular pathways. They study the relationship between EBV and multiple human malignancies, including lymphomas, gastric and nasopharyngeal carcinoma, how EBV subverts innate and adaptive immune pathways, epigenetic and metabolic pathways to establish latency and ultimately to reactivate its lytic cycle. The Gewurz lab uses whole exome approaches to investigate rare primary immunodeficiency syndromes manifest by chronic active EBV and EBV-associated lymphomas. The Gewurz lab also uses a multi-disciplinary approach to identify host-directed antiviral targets to block replication of SARS-CoV-2. They are using whole cell metabolomic profiling to identify epithelial cell metabolic pathways that support massive coronavirus-driven RNA production, CRISPR/Cas9 approaches to identify host factors critical for coronavirus replication, and proteomic approaches to characterise how coronavirus infection remodels infected cell proteomes and compartments important for viral replication.